GlassScriptPhysician profile
Daniel M Kambic
NPI 1487616991
$20,189.52
in general payments reported to CMS, 2019-2025
54 companies · $3,336 in 2025
The $3,336 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,430 · 2020: $1,610 · 2021: $3,082 · 2022: $3,056 · 2023: $3,131 · 2024: $3,546 · 2025: $3,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,012.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,312.70 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,216.64 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $2,044.98 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,935.48 | 2019-2025 | Jardiance, Stiolto Respimat, Synjardy |
| Abbvie INC. | $1,892.05 | 2021-2025 | |
| Lilly USA, LLC | $1,394.99 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,082.60 | 2019-2025 | Evenity, Prolia, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,015.30 | 2019-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $688.32 | 2022-2025 | |
| Pfizer INC. | $618.03 | 2019-2025 | |
| Amarin Pharma, INC. | $458.87 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $452.59 | 2019-2024 | Xarelto |
| Abbott Laboratories | $392.32 | 2021-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $290.00 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $260.24 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $242.87 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $232.35 | 2021-2025 | Camzyos, Eliquis |
| Astellas Pharma US INC | $215.70 | 2019-2023 | Veozah, Myrbetriq |
| Dexcom, INC. | $187.78 | 2022-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $178.18 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $173.13 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $164.57 | 2020-2025 | Rexulti |
| Sanofi Pasteur INC. | $131.49 | 2022-2023 | |
| Shield Therapeutics INC | $122.18 | 2023-2025 | Accrufer |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $113.85 | 2024-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $112.36 | 2019-2024 | Trintellix |
| Cequr Corporation | $111.48 | 2023-2025 | Cequr Simplicity |
| Kowa Pharmaceuticals America, INC. | $109.40 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $105.42 | 2020-2021 | |
| Allergan, INC. | $87.11 | 2020-2022 | |
| Axsome Therapeutics, INC. | $79.03 | 2025 | Symbravo, Auvelity |
| Phathom Pharmaceuticals, INC. | $73.08 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $68.97 | 2019-2022 | |
| Verona Pharma, INC. | $67.40 | 2025 | Ohtuvayre |
| Inspire Medical Systems, INC. | $48.32 | 2024-2025 | Inspire |
| Genentech USA, INC. | $42.30 | 2020-2021 | |
| Tactile Systems Technology INC | $40.35 | 2021-2023 | Flexitouch Plus, Entre Plus |
| Vanda Pharmaceuticals INC. | $37.08 | 2025 | Fanapt |
| Corcept Therapeutics | $35.56 | 2024 | Korlym |
| Sumitomo Pharma America, INC. | $34.69 | 2025 | Gemtesa |
| Medtronic, INC. | $33.37 | 2024 | Interstim |
| Idorsia Pharmaceuticals US INC | $31.47 | 2023-2024 | Quviviq |
| Alnylam Pharmaceuticals INC. | $30.73 | 2022-2023 | Givlaari |
| Radius Health, INC. | $30.41 | 2025 | |
| Philips North America LLC | $30.13 | 2022 | |
| Seqirus USA INC | $25.46 | 2025 | Flucelvax, Fluad |
| Organon LLC | $23.31 | 2021 | |
| Esperion Therapeutics, INC. | $18.90 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $18.37 | 2025 | Neffy |
| Daiichi Sankyo INC. | $17.63 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $17.14 | 2025 | Uptravi |
| Neurocrine Biosciences, INC. | $14.78 | 2023 | Ingrezza |
| Alkermes, INC. | $14.46 | 2019 | |
| Ibsa Pharma INC. | $13.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kambic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.